Consumer staples got sold off hard over the past year. GLP-1 fears, private label pressure, and slower volumes across the sector. The whole basket got repriced lower, and the market stopped looking closely at individual names.
That is exactly when the interesting ones deserve a second look.
Church & Dwight has spent the past few years folding high-margin premium brands into a portfolio that the market still prices like it is mostly a legacy household products business.
The story underneath is more interesting than the multiple suggests, and the latest quarter gave you the clearest evidence yet that the transition is working.
Tesla Upgrade Revealed (Sponsored)
One analyst says investors should consider rotating out of overpriced AI leaders and into smaller names with more room to run.
His top idea is a little-known company that recently partnered with Nvidia and could gain an edge in the autonomous vehicle market.
He’s calling it “an upgrade to Tesla stock.”
See the Stock He Says Could Outrun Tesla
What Just Happened
Organic growth accelerated when it mattered most
Church & Dwight (NYSE: CHD) reported Q2 revenue of $1.53 billion, up 1.6% year-on-year and 1.8% ahead of estimates. The reported growth looks modest. The organic number tells a different story.
Organic sales grew 5.8% year-on-year, the fastest pace in several quarters. That came from innovation, distribution wins, and higher marketing behind the core brands.
When you strip away acquisitions and currency noise, the underlying business is moving faster than the surface numbers suggest.
Adjusted EPS was $0.89, essentially in line with the $0.90 consensus. Free cash flow margin expanded to 16.8% from 13.8% a year ago. The gap between flat EPS and meaningfully higher cash generation is where the real operating progress shows up.
What management expects next
Full-year guidance was raised for sales, EPS, and cash flow.
The honest complication: Q3 EPS guidance came in at $0.89, below analyst expectations of $0.94. Management is flagging higher marketing investment and ongoing macro uncertainty.
A soft Q3 could create near-term pressure even with the full-year raise intact. Worth knowing before sizing in.
Retirement Stock Revealed (Sponsored)
For years, Berkshire Hathaway was one analyst’s favorite retirement stock.
Now he says he may have found an even better long-term opportunity—one tied to AI and another critical U.S. industry.
He believes the company offers both strong dividend income and significant upside in the years ahead.
See the Name and Ticker of America’s Next Great Retirement Stock.
*This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
The Two Brands Doing the Real Work
TheraBreath and Hero are outgrowing everything else in the portfolio
The case for owning this at a premium multiple is not Arm & Hammer. It is TheraBreath and Hero.
TheraBreath is the number-two premium oral care brand in the US, still growing at double-digit rates. Hero went from a social media phenomenon to a genuine category leader in acne care, now with real shelf presence at mass and specialty retail.
Both brands carry higher gross margins than the legacy portfolio. Both are significantly under-penetrated internationally.
That international expansion is still early. Europe and Asia represent real runway that is not yet showing up meaningfully in reported numbers.
The acquisition playbook keeps compounding
Management buys niche premium brands, integrates them into existing distribution, runs them better than the previous owner did, and then pushes them internationally where the brand has minimal presence.
It worked with TheraBreath. It is working with Hero. Touchland, added more recently, fits the same profile.
Every deal shifts blended gross margins higher. Every successful international launch extends the growth runway without having to build brand awareness from scratch. The model is quiet, but it keeps compounding.
Protect Purchasing Power (Sponsored)
When the U.S. left the gold standard in 1971, the rules of money changed almost overnight.
Today, with inflation concerns, heavy central-bank gold buying, and questions around the dollar, some investors are taking another look at physical gold for retirement diversification.
This free guide explains the history, the risks, and how eligible retirement funds may be used for gold without triggering an immediate taxable distribution.
See How Retirement Investors Are Adding Physical Gold Before the Next Big Shift
Margin Math and Cash Generation
The cash story is more important than the EPS story right now
EPS was flat year on year. Free cash flow margin improved by three full percentage points in a single quarter. That gap is important.
Integration costs from past acquisitions are dropping out. The product mix is tilting toward higher-margin premium brands. Working capital tightened. The business is generating significantly more cash per dollar of revenue than it was twelve months ago.
The back half is where the gross margin story gets real
Commodity cost comparisons ease in the back half. Management has been explicit about expecting gross margin acceleration.
If that lands, the earnings math shifts. A company that held EPS roughly flat through a tough input cost environment gets meaningful operating leverage as those costs normalize.
Analysts who have not updated FY27 models with a cleaner gross margin assumption are likely underestimating the earnings power.
Valuation, Analyst Consensus, and Insider Activity
You are paying a premium. Is the setup worth it?
The shares recently traded around $99 to $101. At roughly 26 times forward earnings with a PEG ratio above 3, this is not cheap by any measure. That is expensive territory for consumer staples regardless of the brand quality story.
Analyst consensus is currently Hold, not Buy. Average target around $104. Nine analysts rate it Buy. Eight say Hold. One carries an Underweight with a target well below the current price. The analyst community is not collectively pounding the table here.
The bull case requires organic growth to hold above 3% in the back half, gross margins to inflect higher, and FY27 estimates to move up. Those are reasonable expectations, but you need all three to justify the multiple you are paying today.
The insider activity deserves a mention
In the past 90 days, insiders sold roughly 59,000 shares worth approximately $5.9 million. Multiple senior executives and a director participated. Zero insider purchases in the same period.
Executives sell for a lot of reasons unrelated to outlook. But when the valuation demands above-consensus execution and the people closest to the business are consistent sellers, that is a signal to size conservatively rather than aggressively.
One Number You Should Treat Carefully
5.8% organic growth sounds strong. Here is what is underneath it.
The organic growth number was a genuine beat and better than most expected. But most of the acceleration came from pricing benefits and innovation investments made in prior periods, not a structural step change in underlying demand.
Volume growth was more modest. Distribution wins helped. Marketing pulled some demand forward.
Full-year organic guidance is 3% to 4%. Management is effectively telling you Q2 was a strong quarter inside a more moderate annual trajectory.
The 5.8% quarter will not repeat every quarter, and if you buy expecting it to, the setup will disappoint. Watch the volume component specifically, not just the headline organic number.
Trivia: The "Buffett Indicator" — total U.S. stock market capitalization divided by GDP — is the valuation measure Warren Buffett once called the best single gauge of where stock valuations stand. What did he call it?
What Could Trip It Up
Q3 guidance already set a low bar. At $0.89 versus expectations of $0.94, management signaled near-term headwinds before the quarter even started. At 26 times earnings, soft prints get repriced.
The premium brand thesis requires continued execution. TheraBreath and Hero need to hold pricing as private label chases them in adjacent categories. Track the channel data through the fall.
GLP-1 tail risk remains open. The concern that weight-loss drugs structurally reduce demand in certain consumer categories has not materialized meaningfully yet. If it does in oral care or personal care specifically, the premium brand growth story gets more complicated.
Insider selling is a consistent signal. Not alarming in isolation, but at a multiple that prices in optimism, it is another reason to size the position with discipline.
My Take
The underlying business is doing genuinely interesting things. TheraBreath and Hero are real growth engines with real international runway ahead. The free cash flow improvement is structural, not a fluke. Management has a strong track record of acquiring brands and running them better.
But the current price does not leave much room for error.
Q3 guidance already disappointed. Insiders are sellers. The PEG ratio is expensive. And the analyst community is split nearly evenly between Buy and Hold.
The better entry is on weakness. A pullback toward $92 to $95 on a softer Q3 print makes the risk/reward meaningfully more attractive.
At that level, you are owning the organic growth story and gross margin inflection as genuine opportunities rather than assumptions already embedded in the multiple.
Hold if you own it. Wait before initiating or adding.
Action Recap
Looking to buy? Wait for a pullback toward $92 to $95. The story is real, but the current multiple prices in execution that has not been fully delivered yet.
Already own it? Hold through Q3. Watch gross margin direction and whether organic growth holds above 3%. A soft quarter with the full-year guide intact is manageable. A guide-down is not.
Main risk to respect: Q3 guidance already came in soft, insiders are consistent sellers, and at 26 times forward earnings, any miss compresses the multiple quickly.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any [blank] stocks you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
